Showing papers by "Timothy J Wilt published in 1995"

Distribution of lipids in 8,500 men with coronary artery disease

Abstract: In the present study we measured fasting lipid profiles in over 8,500 community-living men with coronary artery disease (CAD) to determine the distribution of lipid abnormalities in this population: 81% were white and 16% black; mean age 62.9 +/- 8 years; mean total cholesterol 214 +/- 41 mg/dl; low-density lipoprotein (LDL) cholesterol 140 +/- 37 mg/dl; high-density lipoprotein (HDL) cholesterol 39 +/- 11 mg/dl; and triglycerides 190 +/- 142 mg/dl. After adjusting for age, the only significant difference between blacks and whites was a higher HDL cholesterol in blacks (45 vs 38 mg/dl, p or = 100 mg/dl), 38% had low HDL cholesterol ( 200 mg/dl). We estimated that 42% of men with CAD would be definite candidates for cholesterol-lowering medication according to the National Cholesterol Education Program guidelines and that 41% of those in whom cholesterol-lowering medication would not be definitely indicated had low levels of HDL cholesterol. We conclude that (1) black men with CAD have substantially higher HDL cholesterol than white men, (2) almost 90% of male patients with CAD are candidates for dietary intervention and > 40% may need medications to lower LDL cholesterol, and (3) 40% of patients without a definite indication for cholesterol-lowering medications have low levels of HDL cholesterol.

The prostate cancer intervention versus observation trial (PIVOT). A randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer

Abstract: The Prostate cancer Intervention Versus Observation Trial (PIVOT) is a randomized trial designed to determine whether early intervention with radical prostatectomy or expectant management should be the preferred treatment for men with clinically localized prostate cancer. This trial will enroll 2000 participants younger than 75 years of age from 75 Department of Veterans Affairs and National Cancer Institute medical centers. Men will be excluded if they are judged not to be candidates for radical prostatectomy. Eligible participants will be randomized over a 3-year period and followed for a minimum of 12 years. Follow-up data will include urologic symptoms, disease- and treatment-related morbidity, and disease-specific and overall quality of life. Evidence of disease persistence, recurrence, or progression will be measured by questionnaire, physical examination, prostate specific antigen measure, and bone scan. The primary study end point will be all-cause mortality. Secondary outcomes will include prostate cancer and treatment-specific morbidity and mortality, health status, predictors of disease-specific outcomes, and cost-effectiveness. Cancer 1995 ;75 :1963-8.